The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma

Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman, Stephen Opat, Alessandra Tedeschi, Kim Linton, Pamela McKay, Bei Hu, Henry Chan, Jie Jin, Magdalena Sobieraj-Teague, Pier Luigi Zinzani, Morton Coleman, Catherine Thieblemont, Peter Browett, Xiaoyan Ke, Mingyuan Sun, Robert Marcus, Craig A Portell, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A Hawkes, Sally Mapp, Shir-Jing Ho, Dipti Talaulikar, Ke-Shu Zhou, Melannie Co, Xiaotong Li, Wenxiao Zhou, Massimo Cappellini, Chris Tankersley, Jane Huang, Judith Trotman

Abstract

Purpose: Marginal zone lymphoma (MZL) is an uncommon non-Hodgkin lymphoma with malignant cells that exhibit a consistent dependency on B-cell receptor signaling. We evaluated the efficacy and safety of zanubrutinib, a next-generation selective Bruton tyrosine kinase inhibitor, in patients with relapsed/refractory (R/R) MZL.

Patients and methods: Patients with R/R MZL were enrolled in the phase II MAGNOLIA (BGB-3111-214) study. The primary endpoint was overall response rate (ORR) as determined by an independent review committee (IRC) based on the Lugano 2014 classification.

Results: Sixty-eight patients were enrolled. After a median follow-up of 15.7 months (range, 1.6 to 21.9 months), the IRC-assessed ORR was 68.2% and complete response (CR) was 25.8%. The ORR by investigator assessment was 74.2%, and the CR rate was 25.8%. The median duration of response (DOR) and median progression-free survival (PFS) by independent review was not reached. The IRC-assessed DOR rate at 12 months was 93.0%, and IRC-assessed PFS rate was 82.5% at both 12 and 15 months. Treatment was well tolerated with the majority of adverse events (AE) being grade 1 or 2. The most common AEs were diarrhea (22.1%), contusion (20.6%), and constipation (14.7%). Atrial fibrillation/flutter was reported in 2 patients; 1 patient had grade 3 hypertension. No patient experienced major hemorrhage. In total, 4 patients discontinued treatment due to AEs, none of which were considered treatment-related by the investigators.

Conclusions: Zanubrutinib demonstrated high ORR and CR rate with durable disease control and a favorable safety profile in patients with R/R MZL.

©2021 The Authors; Published by the American Association for Cancer Research.

Figures

Figure 1.
Figure 1.
A, Kaplan–Meier plot of duration of response with zanubrutinib per IRC assessment based on Lugano classification (15) for patients with MZL in the MAGNOLIA study (BGB-3111–214). Only patients with either PR or CR were included. B, Kaplan–Meier plot of PFS with zanubrutinib per IRC assessment based on Lugano classification (15) for patients with MZL in the MAGNOLIA study (BGB-3111–214). CIs were calculated using a generalized Brookmeyer and Crowley method.
Figure 2.
Figure 2.
Forest plot representing subgroup analysis of ORR per IRC assessment based on Lugano classification (15) for patients with MZL in the MAGNOLIA study (BGB-3111–214). CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone. aTwo-sided Clopper–Pearson 95% CIs for ORR.
Figure 3.
Figure 3.
ORR per IRC assessment based on Lugano classification (15) for MZL patients in the MAGNOLIA study (BGB-3111–214).

References

    1. Kahl B, Yang D. Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. Hematology Am Soc Hematol Educ Program 2008;359–64.
    1. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. . The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016;127:2375–90.
    1. Denlinger NM, Epperla N, William BM. Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. Cancer Manag Res 2018;10:615–24.
    1. Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, et al. . Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood 2017;129:2224–32.
    1. Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. . AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:1188–99.
    1. Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, et al. . Umbralisib, a dual PI3Kδ/CK1ε inhibitor in patients with relapsed or refractory indolent lymphoma. J Clin Oncol 2021:JCO2003433.
    1. Revlimid (lenalidomide) [US prescribing information]. Summit, NJ: Celgene Corp; 2019.
    1. Matasar MJ, Capra M, Özcan M, Lv F, Li W, Yañez E, et al. . Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:678–89.
    1. Phillips TJ, Corradini P, Gurion R, Patti C, Tani M, Avigdor A, et al. . Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory marginal zone lymphoma (CITADEL-204). Blood 2020;136:27–8.
    1. Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol 2016;9:80.
    1. Tam CS, Opat S, D'Sa S, Jurczak W, Lee H-P, Cull G, et al. . A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020;136:2038–50.
    1. Tam CS, Robak T, Ghia P, Kahl BS, Walker P, Janowski W, et al. . Efficacy and safety of zanubrutinib in patients with treatment-naive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with Del(17p): initial results from arm C of the Sequoia (BGB-3111–304) trial. Blood 2019;134:499.
    1. Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. . Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase. Clin Cancer Res 2020;26:4216–24.
    1. Brukinsa (zanubrutinib) [US prescribing information]. San Mateo, CA: BeiGene USA, Inc; 2019.
    1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–68.
    1. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29–41.
    1. Sindel A, Al-Juhaishi T, Yazbeck V. Marginal zone lymphoma: state-of-the-art treatment. Curr Treat Options in Oncol 2019;20:90.
    1. Tam CSL, Opat S, D'Sa S, Jurczak W, Lee H-P, Cull G, et al. . ASPEN: results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). J Clin Oncol 2020;38:(abstr 8007).

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit